Sellas Life Sciences Group is a biotechnology business based in the US. Sellas Life Sciences Group shares (SLS) are listed on the NASDAQ and all prices are listed in US Dollars. Sellas Life Sciences Group employs 11 staff and has a trailing 12-month revenue of around $1 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $3.30 |
|---|---|
| 52-week range | $1.77 - $7.40 |
| 50-day moving average | $2.65 |
| 200-day moving average | $2.81 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.23 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.3 from 2023-02-01
| 1 week (2023-01-26) | -2.94% |
|---|---|
| 1 month (2022-12-30) | 39.83% |
| 3 months (2022-11-02) | -17.29% |
| 6 months (2022-08-02) | 24.06% |
| 1 year (2022-02-01) | -40.54% |
|---|---|
| 2 years (2021-02-02) | -59.66% |
| 3 years (2020-01-31) | 18.28% |
| 5 years (2018-02-02) | 5.93 |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $7.4 million |
| Return on assets TTM | -55.55% |
| Return on equity TTM | -197.83% |
| Profit margin | 0% |
| Book value | $0.61 |
| Market capitalisation | $67.9 million |
TTM: trailing 12 months
We're not expecting Sellas Life Sciences Group to pay a dividend over the next 12 months.
Sellas Life Sciences Group's shares were split on a 1:50 basis on 7 November 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sellas Life Sciences Group shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Sellas Life Sciences Group shares which in turn could have impacted Sellas Life Sciences Group's share price.
Over the last 12 months, Sellas Life Sciences Group's shares have ranged in value from as little as $1.77 up to $7.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sellas Life Sciences Group's is 2.1636. This would suggest that Sellas Life Sciences Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
SELLAS Life Sciences Group, Inc. , a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co. , Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.